Li Zhang

Huaqiang Zhou, W. Fang, Yu-xiang Ma, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chinese a Nti鄄 Cancer a Ssociation

Jing Zhang, Hong Zhao, Li Zhang, 2022 .

Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy

Haifeng Li, Yongluo Jiang, Sha Fu, 2023, iScience.

AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial

M. Zhou, W. Zhang, Yanqiu Zhao, 2023, EClinicalMedicine.

Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.

Jing Sun, Kehui Chen, W. Fang, 2023, Clinical lung cancer.

Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study

J. Wang, W. Fang, Yun-peng Yang, 2023, Cancer Chemotherapy and Pharmacology.

Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis

C. Xue, W. Fang, Yun-peng Yang, 2016, Oncotarget.

A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).

N. Yang, Yu-xiang Ma, Yun Fan, 2023, Lung cancer.

DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target

Li Zhang, Wei Jiang, Maojian Chen, 2024, Journal of translational medicine.

Neurokinin‐1 Receptor Antagonist‐Based Triple Regimens in Preventing Chemotherapy‐Induced Nausea and Vomiting: A Network Meta‐Analysis

Y. Huang, Li Zhang, W. Fang, 2017, Journal of the National Cancer Institute.

The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

Lin Zhang, F. Luo, J. Zhan, 2023, Cellular & molecular immunology.

Publisher Correction: Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC

Le Zhang, Junchao Cai, Yongbo Huang, 2018, Nature Communications.

KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial

Yuanyuan Zhao, Jingxun Wu, Gang Chen, 2024, Cell reports. Medicine.

Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma

W. Fang, Yuanyuan Zhao, F. Luo, 2024, Cell reports. Medicine.

Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis

Jian-hua Chang, Shen Zhao, Li Zhang, 2024, Lung Cancer.

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

W. Feng, K. Ma, G. Selvaggi, 2024, Cancer communications.